GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Other Current Receivables

Tvardi Therapeutics (LTS:0HTC) Other Current Receivables : £0.78 Mil (As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Other Current Receivables?

Tvardi Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2025 was £0.78 Mil.

Tvardi Therapeutics's quarterly Other Current Receivables stayed the same from Mar. 2024 (£0.00 Mil) to Sep. 2024 (£0.00 Mil) but then increased from Sep. 2024 (£0.00 Mil) to Mar. 2025 (£0.78 Mil).


Tvardi Therapeutics Other Current Receivables Historical Data

The historical data trend for Tvardi Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Other Current Receivables Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23
Other Current Receivables
- -

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Sep24 Mar25
Other Current Receivables - - - - 0.78

Tvardi Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Tvardi Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Tvardi Therapeutics Business Description

Traded in Other Exchanges
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines